Apollon Formularies PLC (APOL.AQ)

0.0300 0.0000 (0.00%) At close: 03:52PM BST

Apollon Formularies PLC

34 North Quay
Douglas IM1 4LB
Isle of Man
44 20 7907 9314
https://www.apollon.org.uk

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Stephen D. Barnhill Jr., M.D.	Chairman & CEO	N/A	N/A	1959
Mr. Stene Jacobs	Head of Corporate Development & COO	N/A	N/A	N/A
Dr. Herbert A. Fritsche Jr., M.D., Ph.D.	Chief Science Officer, Member of Advisory Board, Consultant & Director	N/A	N/A	1941
Mr. Paul Burke	CEO of Apollion Formularies Jamaica	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Apollon Formularies PLC operates as a medical cannabis pharmaceutical company. It offers hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products, such as cannabis oil vape, oral tincture, and perscribed capsules under the Apollon NAUSEA, Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER names. Apollon Formularies PLC was founded in 2014 and is based in Douglas, the United Kingdom.

Corporate governance

Apollon Formularies PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.